STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
Interventions: BIOLOGICAL: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|BIOLOGICAL: Sargramostim
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)|University of Wisconsin, Madison